TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Buy" from Analysts

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) have been given a consensus rating of "Buy" by the eight analysts that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $12.08.

A number of research firms recently issued reports on TLSI. Roth Mkm began coverage on shares of TriSalus Life Sciences in a research report on Monday, November 11th. They set a "buy" rating and a $11.00 target price for the company. Northland Capmk raised TriSalus Life Sciences to a "strong-buy" rating in a research note on Friday, October 25th. Roth Capital raised shares of TriSalus Life Sciences to a "strong-buy" rating in a report on Monday, November 11th. Oppenheimer initiated coverage on shares of TriSalus Life Sciences in a research report on Monday, September 16th. They issued an "outperform" rating and a $10.00 price target on the stock. Finally, Canaccord Genuity Group decreased their target price on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a "buy" rating for the company in a research note on Friday, November 15th.

Insider Buying and Selling

In related news, CEO Mary T. Szela bought 7,520 shares of the business's stock in a transaction on Thursday, September 12th. The stock was acquired at an average cost of $5.20 per share, with a total value of $39,104.00. Following the purchase, the chief executive officer now directly owns 377,382 shares of the company's stock, valued at $1,962,386.40. The trade was a 2.03 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 32.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Walleye Capital LLC acquired a new stake in TriSalus Life Sciences during the third quarter worth approximately $66,000. Virtu Financial LLC acquired a new stake in TriSalus Life Sciences during the 3rd quarter valued at $92,000. Vestcor Inc acquired a new position in TriSalus Life Sciences in the third quarter worth approximately $108,000. MSD Partners L.P. bought a new position in TriSalus Life Sciences in the 3rd quarter worth $184,000. Finally, Wolverine Asset Management LLC bought a new position in TriSalus Life Sciences in the second quarter worth $240,000. Hedge funds and other institutional investors own 2.58% of the company's stock.

TriSalus Life Sciences Stock Performance

Shares of TLSI traded down $0.05 during midday trading on Wednesday, hitting $4.07. The company had a trading volume of 14,199 shares, compared to its average volume of 38,466. TriSalus Life Sciences has a 1 year low of $3.32 and a 1 year high of $10.42. The company's 50-day simple moving average is $4.29 and its 200-day simple moving average is $5.68. The firm has a market capitalization of $124.09 million, a P/E ratio of -1.65 and a beta of 0.49.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.